Cargando…
Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
Regorafenib is a broad-spectrum oral multikinase inhibitor that targets several angiogenic, oncogenic, and stromal receptor tyrosine kinases that support the tumor microenvironment. Results from the pivotal Phase III Patients with Metastatic Colorectal Cancer Treated with Regorafenib or Placebo Afte...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949557/ https://www.ncbi.nlm.nih.gov/pubmed/24623990 http://dx.doi.org/10.2147/CMAR.S52217 |